Tags : INC280

Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation

Shots: The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints Capmatinib […]Read More